Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XFOR 
X4 Pharmaceuticals Inc (XFOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: XFOR (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 11.61% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.50M USD | Price to earnings Ratio - | 1Y Target Price 2.67 |
Price to earnings Ratio - | 1Y Target Price 2.67 | ||
Volume (30-day avg) 1529260 | Beta 0.39 | 52 Weeks Range 0.22 - 1.54 | Updated Date 04/1/2025 |
52 Weeks Range 0.22 - 1.54 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate -0.1575 | Actual -0.2 |
Profitability
Profit Margin - | Operating Margin (TTM) -2490.59% |
Management Effectiveness
Return on Assets (TTM) -60.18% | Return on Equity (TTM) -102.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14526949 | Price to Sales(TTM) 17.22 |
Enterprise Value 14526949 | Price to Sales(TTM) 17.22 | ||
Enterprise Value to Revenue 6.46 | Enterprise Value to EBITDA 1.1 | Shares Outstanding 173662000 | Shares Floating 131670813 |
Shares Outstanding 173662000 | Shares Floating 131670813 | ||
Percent Insiders 1.24 | Percent Institutions 58.14 |
Analyst Ratings
Rating 4.6 | Target Price 3.08 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
X4 Pharmaceuticals Inc
Company Overview
History and Background
X4 Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics to treat diseases resulting from immune system dysfunction. Founded in 2007, it has focused on antagonists of the CXCR4 pathway. Significant milestones include clinical trial initiations and advancement of lead candidate mavorixafor.
Core Business Areas
- Drug Development: Focused on discovering, developing, and commercializing novel therapeutics targeting the CXCR4 pathway.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of mavorixafor in various indications.
Leadership and Structure
Paula Ragan is the CEO. The company has a management team comprising executives with experience in drug development, clinical research, and commercialization. The organizational structure includes departments focused on research, development, clinical operations, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- Mavorixafor: Mavorixafor is a small molecule, oral, selective CXCR4 antagonist. The target indications includes WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis). The competitors is Neupogen(filgrastim) by Amgen (AMGN).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory hurdles. It's driven by innovation and unmet medical needs.
Positioning
X4 Pharmaceuticals is positioned as a player in the rare disease space, focusing on CXCR4-related pathways. Its competitive advantage lies in its proprietary CXCR4 antagonist technology.
Total Addressable Market (TAM)
The TAM for WHIM syndrome and other CXCR4-related disorders is estimated to be in the hundreds of millions of dollars annually. X4 Pharmaceuticals aims to capture a significant portion of this market with mavorixafor.
Upturn SWOT Analysis
Strengths
- Proprietary CXCR4 antagonist technology
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Dependence on single product candidate (mavorixafor)
- High cash burn rate
- Potential clinical trial failures
Opportunities
- Expansion of mavorixafor into additional indications
- Partnerships with larger pharmaceutical companies
- Acquisition of complementary technologies or assets
Threats
- Competition from other companies developing CXCR4 antagonists
- Regulatory setbacks
- Failure to secure adequate funding
Competitors and Market Share
Key Competitors
- Amgen (AMGN)
Competitive Landscape
X4 Pharmaceuticals competes with larger pharmaceutical companies and smaller biotech firms in the rare disease space. Its advantages include its specific focus on the CXCR4 pathway and its proprietary technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the progression of mavorixafor through clinical trials. Growth has depended on achieving positive trial data and funding.
Future Projections: Future growth is dependent on the successful commercialization of mavorixafor and potential expansion into other indications. Analyst estimates vary depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include ongoing clinical trials of mavorixafor and efforts to secure regulatory approval for WHIM syndrome.
Summary
X4 Pharmaceuticals is a biopharmaceutical company focused on developing treatments for immune system dysfunction. Its main asset, mavorixafor, targets the CXCR4 pathway, with potential in WHIM syndrome and other indications. The company faces challenges related to funding, clinical trial success, and competition. Successful commercialization of mavorixafor is key to its future growth, although it also has oppotunities to partner with bigger companies and other acquisitions for market expansion.
Similar Companies
- AMGN
- GILD
- BMRN
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Databases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Financial data is based on available information and may be subject to change. Market share estimates are approximate and based on industry reports and company disclosures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About X4 Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2017-11-16 | CEO, President & Director Dr. Paula Ragan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 143 | Website https://www.x4pharma.com |
Full time employees 143 | Website https://www.x4pharma.com | ||
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.